Find your next paid study

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00001971

~$10 – $675

Phase 3

Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension

This is an open-label, non-randomized trial that will be conducted at three clinical sites, Thomas Jefferson University (TJU), the Hospital of the University o…

Liver DiseasesPortal Hypertension

Thomas Jefferson UniversityNCT05470205

~$10 – $6,250

Nephrotic SyndromeLipodystrophyMetabolic Syndrome+3 more

Prospective Cross-Over Study of the Effects of Meal Macronutrients on Postprandial Lipids

Background: Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with differen…

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT07313787

~$10 – $5,625

Phase 3

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase IIIb Trial to Evaluate the Effect of Survodutide on Cardiac Structure and Function of Participants With Overweight or Obesity and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); (ELEVATE-LIVER)

This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD)…

ObesityMetabolic Dysfunction-associated Steatotic Liver Disease

Boehringer IngelheimNCT07850063

Liver Diseases, Alcoholic

A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment With Efimosfermin Alfa in Adult Participants With Alcohol-related Liver Disease (ALD)

This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in parti…

GlaxoSmithKlineNCT07791043

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Two-Part, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of ALN-PNP With and Without a GLP1R Agonist in Adults With Homozygous PNPLA3-Related Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tir…

Regeneron PharmaceuticalsNCT07527910

~$10 – $8,750

Magnetic Resonance Imaging (MRI)-Based Quantification of Perfusion and Microstructure

This study integrates and evaluates a series of novel MRI methods for quantifying blood perfusion and tissue microstructure. The proposed perfusion and microst…

Liver Diseases

University of Wisconsin, MadisonNCT07634939

~$10 – $750

Chronic Hepatic PruritusCholestatic Liver DiseasePrimary Biliary Cholangitis+2 more

Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus: An Open-Label, Single-Arm, Exploratory Study

The purpose of this research is to investigate the efficacy of nemolizumab in the treatment of adults with moderate to severe chronic hepatic pruritus.

Alcoholic Liver DiseaseCOVID 19 Pneumonia

~$10 – $6,250

Mayo ClinicNCT07843420

Observational

Evaluate the Molecular Mechanisms of HMB-enriched Amino Acid Supplement to Reverse Muscle Loss in Patients With Alcoholic Liver Disease and COVID-19

Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are at risk for severe illness and abrupt or sudden clinical deterior…

The Cleveland ClinicNCT04858412

~$10 – $6,250

Comparison of ALD, NASH, and Healthy Control Patients

The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy con…

ALD - Alcoholic Liver Disease

The Cleveland ClinicNCT03224949

~$10 – $750

Non-Alcoholic Fatty Liver Disease

Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)

A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (N…

Marialena MouzakiNCT06133101

Phase 3

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people wit…

Metabolic Dysfunction-Associated Steatotic Liver Disease